LARIMAR THERAPEUTICS, INC. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
LARIMAR THERAPEUTICS, INC. (LRMR) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of $17.96 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-10.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2018-05-10
- LARIMAR THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-03-31 was $17.96M, a 106.63% increase year-over-year.
- LARIMAR THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-12-31 was $12.69M, a 24.97% decline year-over-year.
- LARIMAR THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-09-30 was $279.00K, a 98.30% decline year-over-year.
- LARIMAR THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was $13.99M, a 266.15% increase year-over-year.
- LARIMAR THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was $35.65M, a 30.71% decline from fiscal 2016.
- LARIMAR THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was $51.45M.
- LARIMAR THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$92.12M.
- LARIMAR THERAPEUTICS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$57.31M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2018-03-31 | $17.96M 10-Q · filed 2018-05-10 | $30.65M derived: sum of 2 quarters · filed 2018-05-10 | $30.93M derived: sum of 3 quarters · filed 2018-05-10 | $44.91M derived: sum of 4 quarters · filed 2018-05-10 |
| 2017-12-31 | $12.69M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | $12.97M derived: sum of 2 quarters · filed 2018-03-09 | $26.96M derived: sum of 3 quarters · filed 2018-03-09 | $35.65M 10-K · filed 2018-03-09 |
| 2017-09-30 | $279.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $14.27M derived: sum of 2 quarters · filed 2017-11-07 | $22.96M 10-Q · filed 2017-11-07 | $39.87M derived: sum of 4 quarters · filed 2018-03-09 |
| 2017-06-30 | $13.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $22.68M 10-Q · filed 2017-08-09 | $39.59M derived: sum of 3 quarters · filed 2018-03-09 | $56.03M derived: sum of 4 quarters · filed 2018-03-09 |
| 2017-03-31 | $8.69M 10-Q · filed 2018-05-10 | $25.60M derived: sum of 2 quarters · filed 2018-03-09 | $42.05M derived: sum of 3 quarters · filed 2018-03-09 | $45.87M derived: sum of 4 quarters · filed 2018-03-09 |
| 2016-12-31 | $16.91M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | $33.35M derived: sum of 2 quarters · filed 2018-03-09 | $37.17M derived: sum of 3 quarters · filed 2018-03-09 | $51.45M 10-K · filed 2018-03-09 |
| 2016-09-30 | $16.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $20.26M derived: sum of 2 quarters · filed 2017-11-07 | $34.53M 10-Q · filed 2017-11-07 | $49.99M derived: sum of 4 quarters · filed 2018-03-09 |
| 2016-06-30 | $3.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $18.09M 10-Q · filed 2017-08-09 | $33.55M derived: sum of 3 quarters · filed 2018-03-09 | $5.04M derived: sum of 4 quarters · filed 2018-03-09 |
| 2016-03-31 | $14.27M 10-Q · filed 2017-05-09 | $29.73M derived: sum of 2 quarters · filed 2018-03-09 | $1.22M derived: sum of 3 quarters · filed 2018-03-09 | -$8.12M derived: sum of 4 quarters · filed 2018-03-09 |
| 2015-12-31 | $15.46M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | -$13.05M derived: sum of 2 quarters · filed 2018-03-09 | -$22.39M derived: sum of 3 quarters · filed 2018-03-09 | -$92.12M 10-K · filed 2018-03-09 |
| 2015-09-30 | -$28.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | -$37.85M derived: sum of 2 quarters · filed 2016-11-09 | -$107.58M 10-Q · filed 2016-11-09 | -$164.79M derived: sum of 4 quarters · filed 2017-03-10 |
| 2015-06-30 | -$9.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | -$79.06M 10-Q · filed 2016-08-05 | -$136.28M derived: sum of 3 quarters · filed 2017-03-10 | -$136.31M derived: sum of 4 quarters · filed 2017-03-10 |
| 2015-03-31 | -$69.73M 10-Q · filed 2016-05-10 | -$126.94M derived: sum of 2 quarters · filed 2017-03-10 | -$126.98M derived: sum of 3 quarters · filed 2017-03-10 | -$127.04M derived: sum of 4 quarters · filed 2017-03-10 |
| 2014-12-31 | -$57.22M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-10 | -$57.25M derived: sum of 2 quarters · filed 2017-03-10 | -$57.31M derived: sum of 3 quarters · filed 2017-03-10 | -$57.31M 10-K · filed 2017-03-10 |
| 2014-09-30 | -$31.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13 | -$94.00K derived: sum of 2 quarters · filed 2015-11-13 | -$99.00K 10-Q · filed 2015-11-13 | -$107.00K derived: sum of 4 quarters · filed 2016-03-15 |
| 2014-06-30 | -$63.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-14 | -$68.00K 10-Q · filed 2015-08-14 | -$76.00K derived: sum of 3 quarters · filed 2016-03-15 | -$77.00K derived: sum of 4 quarters · filed 2016-03-15 |
| 2014-03-31 | -$5.00K 10-Q · filed 2015-05-14 | -$13.00K derived: sum of 2 quarters · filed 2016-03-15 | -$14.00K derived: sum of 3 quarters · filed 2016-03-15 | |
| 2013-12-31 | -$8.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | -$9.00K derived: sum of 2 quarters · filed 2016-03-15 | -$17.00K 10-K · filed 2016-03-15 | |
| 2013-09-30 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13 | -$9.00K 10-Q · filed 2014-11-13 | ||
| 2013-06-30 | -$8.00K 10-Q · filed 2014-08-14 | |||
| 2012-12-31 | -$2.00K 10-K · filed 2015-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |